The study will evaluate continuous lung sound monitoring for the early detection of pulmonary edema and prevention of complications in critically ill ICU patients.
Philadelphia, PA, February 20, 2025 — Strados Labs, a medical technology company focused on improving respiratory health, is proud to announce a new collaboration with Beth Israel Deaconess Medical Center (BIDMC). The upcoming study will evaluate the use of Strados Labs’ RESP® Biosensor, an FDA-cleared wearable stethoscope technology, for the early detection of pulmonary edema in critically ill patients on mechanical ventilation (MV). This pilot study is scheduled to begin at the end of February 2025, enrolling 20 patients, with an anticipated duration of 12 months.
This single-center, prospective, observational study will evaluate whether abnormal lung sounds captured by the RESP Biosensor precede currently observed markers and signs of pulmonary edema—a common and life-threatening complication in critically ill patients. The device’s performance will be compared to existing monitoring methods, including daily chest X-rays, intermittent clinical assessments, and fluid intake and output (I&O) tracking.
“Patients on mechanical ventilation are at high risk of developing serious pulmonary complications such as pulmonary edema. These complications can lead to various adverse outcomes. Continuous lung sound monitoring may allow us to detect these complications earlier than we currently can with our existing patient monitoring methods.” said Dr. John Lee, PhD, MD, Principal Investigator and Attending Physician at BIDMC. “We are excited to collaborate with Strados Labs on this pilot study, which could lead to further research in this area.
The RESP Biosensor, an FDA 510(k) cleared, CE-marked wearable device, is designed to continuously capture lung sounds such as cough, wheeze and crackles associated with worsening respiratory health. The technology has been used in several patient populations and disease states including chronic cough, COPD, asthma, IPF and heart failure. This study will be the first time the RESP Biosensor will be used to monitor patients on MV to detect pulmonary edema.
“Pulmonary edema presents significant challenges in the ICU, with delayed detection often leading to poorer outcomes for patients,” said Nick Delmonico, CEO & Cofounder at Strados Labs. “We’re excited to collaborate with the esteemed team at BIDMC to explore whether continuous monitoring of lung sounds could lead to earlier and prompt interventions in pulmonary edema.”
This study marks another step in a broader effort to evaluate the RESP Biosensor’s ability to enhance patient care and outcomes across several disease areas. The findings are expected to guide future studies and pave the way for new applications for continuous lung sound monitoring.
About Strados Labs
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory diseases. Enabling remote monitoring of lung health, Strados Labs’ RESP Biosensor allows clinicians to continuously measure patients’ lung sounds such as cough and wheeze that can indicate an exacerbation or reduced quality of life. The technology is used to assist drug developers in demonstrating treatment efficacy in clinical trials and to support clinicians in surveilling and managing patients. The RESP Biosensor is FDA-cleared, CE marked and HIPAA compliant, backed by multiple awards and clinical publications. Strados Labs is privately owned and based in Philadelphia, PA.
For more information, visit Stradoslabs.com or follow us on LinkedIn and X.
About Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center is a leading academic medical center, where extraordinary care is supported by high-quality education and research. BIDMC is a teaching affiliate of Harvard Medical School and consistently ranks as a national leader among independent hospitals in National Institutes of Health funding. BIDMC is the official hospital of the Boston Red Sox.
Beth Israel Deaconess Medical Center is a part of Beth Israel Lahey Health, a health care system that brings together academic medical centers and teaching hospitals, community and specialty hospitals, more than 4,700 physicians and 39,000 employees in a shared mission to expand access to great care and advance the science and practice of medicine through groundbreaking research and education.
Media Contact:
Gabe Steerman
gabe@stradoslabs.com
stradoslabs.com